---
title: "Ubrelvy (ubrogepant) in acute treatment of migraine: Dosing and administration questions"
description: "Dosing and administration questions on Ubrelvy (ubrogepant) in acute treatment of migraine, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Treatment combinations, Administration, Dosing, and Prescribing. Questions: Were migraine preventive medications allowed in Ubrelvy clinical trials? Can Ubrelvy be taken with food? What is the Ubrelvy dose for acute migraine? What is the maximum dose of Ubrelvy in 24 hours? 3 further questions follow. 7 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Ubrelvy (ubrogepant) in acute treatment of migraine: Dosing and administration questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Ubrelvy](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf)

## Treatment combinations

<a id="ubrelvy-with-preventive-medications"></a>

### Were migraine preventive medications allowed in Ubrelvy clinical trials?

> “In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline.<sup>1,2</sup> None of these patients were on concomitant preventive medications that act on the CGRP pathway<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=In%20clinical%20trials%2C%20patients%20were,that%20act%20on%20the%20CGRP)

> “Up to 23% of patients were 
> taking preventive medications for migraine at baseline. None of these patients were on 
> concomitant preventive medication that act on the CGRP pathway.”

Source: [UBRELVY: Prescribing information, page 12, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=12)

Note: The first passage is from the dosing page of the Ubrelvy HCP site, which cites the Prescribing Information and Ailani et al., Headache 2020 (the 52-week extension trial); the Prescribing Information does not name the preventive medications. The second passage is from the Clinical Studies section of the Prescribing Information and describes Studies 1 and 2.

## Administration

<a id="ubrelvy-food"></a>

### Can Ubrelvy be taken with food?

> “The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “When UBRELVY was administered with a high-fat meal, the time to maximum ubrogepant 
> plasma concentration was delayed by 2 hours and resulted in a 22% reduction in Cmax with no 
> change in AUC. UBRELVY was administered without regard to food in clinical efficacy studies 
> [see Dosage and Administration (2.1)].”

Source: [UBRELVY: Prescribing information, page 9, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=9)

## Dosing

<a id="ubrelvy-dose"></a>

### What is the Ubrelvy dose for acute migraine?

> “The recommended dose of UBRELVY is 50 mg or 100 mg taken orally with or without food.  
> If needed, a second dose may be taken at least 2 hours after the initial dose. The maximum dose 
> in a 24-hour period is 200 mg. The safety of treating more than 8 migraines in a 30-day period 
> has not been established.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

<a id="ubrelvy-max-dose"></a>

### What is the maximum dose of Ubrelvy in 24 hours?

> “The maximum dose 
> in a 24-hour period is 200 mg.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “The maximum dose of UBRELVY
> in a 24-hour period is 200 mg<sup>1</sup>*”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=The%20maximum%20dose%20of%20UBRELVY,a%2024%2Dhour%20period%20is%20200)

> “*Maximum dose may vary for some patient populations. Dose adjustment is recommended for: (1) patients with severe hepatic and/or renal impairment, (2) concomitant use of UBRELVY with weak or moderate CYP3A4 inhibitors, and (3) concomitant use of UBRELVY with BCRP and/or P-gp only inhibitors.”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=%2AMaximum%20dose%20may%20vary%20for,BCRP%20and%2For%20P%2Dgp%20only%20inhibitors.)

<a id="ubrelvy-second-dose"></a>

### When can a second dose of Ubrelvy be taken?

> “A second dose can be taken at least 2 hours after the initial dose, if needed<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=A%20second%20dose%20can%20be,after%20the%20initial%20dose%2C%20if)

> “If needed, a second dose may be taken at least 2 hours after the initial dose.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and with grapefruit juice; avoid second dose within 24 hours<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=Dose%20adjustment%20is%20recommended%20with,avoid%20second%20dose%20within%2024)

<a id="ubrelvy-migraines-per-month"></a>

### Is it safe to treat more than 8 migraines a month with Ubrelvy?

> “The safety of treating more than 8 migraines in a 30-day period 
> has not been established.”

Source: [UBRELVY: Prescribing information, page 2, captured 2026-11-14](https://www.rxabbvie.com/pdf/ubrelvy_pi.pdf#page=2)

> “The safety of treating more than 8 migraines in a 30-day period has not been established<sup>1</sup>”

Source: [UBRELVY: Dosage Instructions + Information, captured 2026-11-14](https://www.ubrelvyhcp.com/dosing#:~:text=The%20safety%20of%20treating%20more,30%2Dday%20period%20has%20not%20been)

## Prescribing

<a id="ubrelvy-prescription"></a>

### What quantity and refills does the Ubrelvy prescription form template show?

> “50 mg Tablets
> Sig: Take as needed
> Dispense 16 tablets
> #11 Refills”

Source: [UBRELVY: US-UBR-210707-Ubrelvy-Prescription-Form_R5.pdf, page 1, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/US-UBR-210707-Ubrelvy-Prescription-Form_R5.pdf#page=1)

> “100 mg Tablets
> Sig: Take as needed
> Dispense 16 tablets
> #11 Refills”

Source: [UBRELVY: US-UBR-210707-Ubrelvy-Prescription-Form_R5.pdf, page 1, captured 2026-11-14](https://www.ubrelvyhcp.com/content/dam/ubrelvyhcp/pdf/US-UBR-210707-Ubrelvy-Prescription-Form_R5.pdf#page=1)

Note: The quantities are those printed on the prescription form template (US-UBR-210707, dated 10/22) that the resources page of the Ubrelvy HCP site links. The Prescribing Information sets no quantity per prescription; it supplies boxes of 10, 16, and 30 tablets and states the second-dose interval, the 200 mg maximum in 24 hours, and that the safety of treating more than 8 migraines in a 30-day period has not been established. The prior authorization guide states that some payers may have quantity limits for Ubrelvy.

## Related pages
- [Medical information: Ubrelvy (ubrogepant): Acute treatment of migraine](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine)
- [Indication](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/safety)
- [Specific populations](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/ubrelvy--acute-treatment-of-migraine/access-and-coverage)
